Impact of ERβ2 on Breast Cancer Treatment Outcomes
Author Information
Author(s): Vinayagam Raman, Sibson D Ross, Holcombe Christopher, Aachi Vijay, Davies Michael PA
Primary Institution: Clatterbridge Cancer Research Trust, University of Liverpool, Royal Liverpool and Broadgreen University Hospital NHS Trust
Hypothesis
ERβ2 may be associated with outcome following adjuvant tamoxifen treatment of breast cancers and therefore be useful as a predictive marker or give some insight into mechanisms of resistance.
Conclusion
High ERβ2 mRNA levels were independently predictive of better outcomes in tamoxifen-treated ERα positive tumors.
Supporting Evidence
- High ERβ2 immunostaining was associated with better outcomes across the cohort.
- ERβ2 mRNA levels were significantly associated with better outcomes in the ERα positive subgroup.
- 34% of cases had both high mRNA and protein levels, which correlated with significantly better outcomes.
Takeaway
This study looked at a protein called ERβ2 in breast cancer and found that higher levels of a specific type of it in the body can help predict how well patients will do after treatment.
Methodology
The study involved immunostaining and quantitative RT-PCR to assess ERβ2 protein and mRNA levels in breast cancer patients receiving adjuvant endocrine therapy.
Potential Biases
Potential biases in patient selection and retrospective data collection.
Limitations
The study was retrospective and may not account for all variables affecting treatment outcomes.
Participant Demographics
141 postmenopausal patients with primary breast cancer, median age 68 years.
Statistical Information
P-Value
0.01
Confidence Interval
0.27–0.90
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website